Izalontamab (SI-B001), a novel EGFR/HER3 bispecific monoclonal antibody, was well-tolerated and exhibited preliminary ...

The American Lung Association released its eighth annual State of Lung Cancer report this past week, noting the five-year ...

A protein involved with cell death can be manipulated to slow or reverse tumor growth, a pair of new studies in mice found.

Trodelvy did not meet the primary endpoint of progression-free survival in the ASCENT-07 trial for HR-positive, HER2-negative ...

Becoming a blockbuster in its third full year on the market put Gilead’s cancer treatment Trodelvy on a course to potentially justify the company’s $21 billion ...

Pre-clinical data for IO Biotech’s next T-win vaccine candidate, IO112 targeting arginase 1, demonstrates anti-tumor activity with dynamic ...

By creating high-resolution cellular and molecular visual maps of lung cancer before and during development, researchers at The University of Texas MD Anderson Cancer Center have discovered that the ...

October brought several updates in the lung cancer field, ranging from notable trial results to patient-centered perspectives ...

Researchers present an overview of treatment and management strategies for patients with HR+/HER2+ breast cancer, including common adverse effects.

Moderna reported third-quarter financial results on Thursday. The transcript from the company's earnings call has been provided below.

Significant progress is being made in the fight against lung cancer, according to a new study from the American Lung ...

Metastatic melanoma cells that have spread to lymph nodes survive by relying on a protein called ferroptosis suppressor ...